Related Experiment Video
Updated: May 20, 2025
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Emerging Role of Molecular Testing in the Management of Non-metastatic Non-small Cell Lung Cancer
1Department of Respiratory Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Abstract:
Advances in targeted therapies and immune checkpoint inhibitors have significantly enhanced survival rates for patients diagnosed with metastatic non-small cell lung cancer (NSCLC). In non-metastatic NSCLC, adding immune checkpoint inhibitors postchemoradiotherapy has led to improved outcomes in stage III disease and during the perioperative period for stages IB-IIIA. Recently, adjuvant osimertinib and alectinib therapy have demonstrated improved survival rates for patients with epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) alterations, respectively; these therapies are now considered standard treatments. Additionally, osimertinib has shown efficacy when administered postchemoradiotherapy in stage III NSCLC. These findings emphasize the importance of assessing EGFR and ALK status to accurately guide treatment decisions for nearly all NSCLC patients, whether they are undergoing curative surgery, chemoradiotherapy, or receiving palliative chemotherapy. This review summarizes recent trials on perioperative and postchemoradiation therapy and advocates for the necessity of molecular testing in non-metastatic NSCLC to enhance patient outcomes.
Insights
Molecular testing for EGFR and ALK alterations is crucial for non-metastatic non-small cell lung cancer (NSCLC) patients. This ensures optimal treatment selection, improving survival outcomes across all stages and therapy types.
Area of Science:
- Oncology
- Thoracic Surgery
- Medical Genetics
Background:
- Targeted therapies and immune checkpoint inhibitors have improved survival in metastatic non-small cell lung cancer (NSCLC).
- For non-metastatic NSCLC, immune checkpoint inhibitors enhance outcomes in stage III disease and perioperative settings (stages IB-IIIA).
- Adjuvant osimertinib (EGFR) and alectinib (ALK) are now standard therapies, demonstrating improved survival.
Purpose of the Study:
- To review recent trials on perioperative and post-chemoradiation therapies for non-metastatic NSCLC.
- To emphasize the necessity of molecular testing (EGFR, ALK) for guiding treatment decisions in NSCLC.
- To advocate for molecular testing to improve patient outcomes in non-metastatic NSCLC.
Main Methods:
- Review of recent clinical trials and therapeutic strategies for non-metastatic non-small cell lung cancer.
- Analysis of data regarding targeted therapies (osimertinib, alectinib) and immune checkpoint inhibitors.
- Assessment of the impact of molecular profiling on treatment selection and patient survival.
Main Results:
- Adjuvant osimertinib and alectinib have shown improved survival in patients with EGFR or ALK alterations, respectively.
- Osimertinib is effective after chemoradiotherapy in stage III NSCLC.
- Molecular testing is essential for guiding treatment in nearly all NSCLC patients, irrespective of treatment modality.
Conclusions:
- Molecular testing for EGFR and ALK alterations is indispensable for non-metastatic NSCLC.
- Personalized treatment strategies based on molecular status significantly improve patient outcomes.
- Routine molecular profiling should be integrated into the management of non-metastatic NSCLC.
More Related Videos
10:35A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction
Published on: April 5, 2018
08:14MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening
Published on: October 26, 2017
